These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27158121)

  • 1. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease.
    Erro R; Picillo M; Vitale C; Palladino R; Amboni M; Moccia M; Pellecchia MT; Barone P
    Parkinsonism Relat Disord; 2016 Jul; 28():137-40. PubMed ID: 27158121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.
    Santangelo G; Vitale C; Picillo M; Cuoco S; Moccia M; Pezzella D; Erro R; Longo K; Vicidomini C; Pellecchia MT; Amboni M; Brunetti A; Salvatore M; Barone P; Pappatà S
    Parkinsonism Relat Disord; 2015 May; 21(5):489-93. PubMed ID: 25753457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
    Song IU; Chung YA; Oh JK; Chung SW
    Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling cognitive and neuropsychiatric heterogeneity in Parkinson's disease.
    van Balkom TD; Vriend C; Berendse HW; Foncke EM; van der Werf YD; van den Heuvel OA; Klein M
    Parkinsonism Relat Disord; 2016 Jul; 28():130-6. PubMed ID: 27215393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.
    Erro R; Pappatà S; Amboni M; Vicidomini C; Longo K; Santangelo G; Picillo M; Vitale C; Moccia M; Giordano F; Brunetti A; Pellecchia MT; Salvatore M; Barone P
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1034-8. PubMed ID: 22789824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
    Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients.
    Erro R; Vitale C; Amboni M; Picillo M; Moccia M; Longo K; Santangelo G; De Rosa A; Allocca R; Giordano F; Orefice G; De Michele G; Santoro L; Pellecchia MT; Barone P
    PLoS One; 2013; 8(8):e70244. PubMed ID: 23936396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease.
    Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D
    Mov Disord; 2014 Dec; 29(14):1802-8. PubMed ID: 25284687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.
    Maillet A; Krack P; Lhommée E; Météreau E; Klinger H; Favre E; Le Bars D; Schmitt E; Bichon A; Pelissier P; Fraix V; Castrioto A; Sgambato-Faure V; Broussolle E; Tremblay L; Thobois S
    Brain; 2016 Sep; 139(Pt 9):2486-502. PubMed ID: 27538418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical subtypes of Parkinson's disease.
    van Rooden SM; Colas F; Martínez-Martín P; Visser M; Verbaan D; Marinus J; Chaudhuri RK; Kok JN; van Hilten JJ
    Mov Disord; 2011 Jan; 26(1):51-8. PubMed ID: 21322019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.
    Colloby SJ; Williams ED; Burn DJ; Lloyd JJ; McKeith IG; O'Brien JT
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1176-85. PubMed ID: 15931516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT.
    Schillaci O; Chiaravalloti A; Pierantozzi M; Di Pietro B; Koch G; Bruni C; Stanzione P; Stefani A
    Int J Mol Med; 2011 Nov; 28(5):881-6. PubMed ID: 21811760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?
    Gerasimou G; Costa DC; Papanastasiou E; Bostanjiopoulou S; Arnaoutoglou M; Moralidis E; Aggelopoulou T; Gotzamani-Psarrakou A
    Ann Nucl Med; 2012 May; 26(4):337-44. PubMed ID: 22382608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation.
    Frosini D; Unti E; Guidoccio F; Del Gamba C; Puccini G; Volterrani D; Bonuccelli U; Ceravolo R
    J Neural Transm (Vienna); 2015 Aug; 122(8):1143-7. PubMed ID: 25613061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?
    Simuni T; Caspell-Garcia C; Coffey C; Lasch S; Tanner C; Marek K;
    Parkinsonism Relat Disord; 2016 Jul; 28():62-7. PubMed ID: 27132498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.